PTC518 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
8ハンチントン病2

8. ハンチントン病


臨床試験数 : 242 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-003852-18-DE
(EUCTR)
06/05/202218/02/2022A Phase 2A study of PTC518 in patients with Huntington's DiseaseA PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE - PIVOT-HD Huntington’s disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: PTC518 tablet 5 mg
Product Code: PTC518
INN or Proposed INN: Not available
Other descriptive name: PTC518
Product Name: PTC518 tablet 20 mg
Product Code: PTC518
INN or Proposed INN: Not available
Other descriptive name: PTC518
PTC Therapeutics, INCNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
162Phase 2France;United States;Australia;Netherlands;Germany;United Kingdom
2NCT05358717
(ClinicalTrials.gov)
April 25, 202227/4/2022A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's DiseaseHuntington DiseaseDrug: PTC518;Drug: PlaceboPTC TherapeuticsNULLRecruiting25 YearsN/AAll162Phase 2United States;Australia;France;Germany;Netherlands;United Kingdom